Cardiac disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 05 Jun 2026 10:52:29 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cardiac disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Dobutamine and Tocilizumab for Patients with Heart Attack at High Risk of Cardiogenic Shock https://clinicaltrials.eu/trial/study-on-dobutamine-and-tocilizumab-for-patients-with-heart-attack-at-high-risk-of-cardiogenic-shock/ Wed, 29 Apr 2026 14:59:04 +0000 https://clinicaltrials.eu/trial/study-on-dobutamine-and-tocilizumab-for-patients-with-heart-attack-at-high-risk-of-cardiogenic-shock/ This clinical trial is focused on patients who have experienced an acute myocardial infarction, commonly known as a heart attack, and are at a high risk of developing cardiogenic shock. Cardiogenic shock is a condition where the heart suddenly can’t pump enough blood to meet the body’s needs. The study is investigating the effects of two treatments: dobutamine and tocilizumab. Dobutamine is a medication that helps the heart pump more effectively, while tocilizumab is a drug that can reduce inflammation in the body. Both medications will be administered through an intravenous infusion, which means they are given directly into a vein.

The purpose of the study is to explore how these treatments might affect certain markers in the blood that indicate heart function and stability. Participants in the study will receive either the medications or a placebo. The study will follow a specific plan where participants will be monitored from the time they are admitted to the hospital until 48 hours after admission. During this time, blood samples will be taken to measure levels of a marker called NTproBNP, which helps assess heart health. Additionally, other tests such as MRI scans and echocardiograms, which are imaging techniques to look at the heart, will be conducted to gather more information about heart function and recovery.

The study aims to provide insights into how these treatments might help prevent complications like cardiogenic shock in patients who have had a heart attack. It will also look at other outcomes such as the size of the heart attack, inflammation levels, and overall heart function. The trial is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, ensuring unbiased results. The study is expected to continue until April 2025.

]]>